The Role of Tumor-Associated Macrophages in Anti-PD-1/PD-L1 Immunotherapy for Lymphoma——Review
10.19746/j.cnki.issn1009-2137.2025.04.043
- VernacularTitle:肿瘤相关巨噬细胞在淋巴瘤抗PD-1/PD-L1免疫治疗中的作用
- Author:
Xing-Hui JIANG
1
;
Yi-Jian CHEN
Author Information
1. 赣南医学院第一临床医学院
- Publication Type:Journal Article
- Keywords:
lymphoma;
tumor-associated macrophage;
PD-1/PD-L1;
tumor microenvironment
- From:
Journal of Experimental Hematology
2025;33(4):1217-1221
- CountryChina
- Language:Chinese
-
Abstract:
Lymphoma is a malignant tumor originating from lymphatic tissue,which can be roughly divided into two types:Hodgkin's lymphoma and non-Hodgkin's lymphoma.It has the characteristics of high recurrence rate,high mortality rate,and short survival time.Tumor cells in lymphoma form a tumor microenvironment(TME)that inhibits host anti-tumor immunity with surrounding immune cells,while tumor-associated macrophages(TAMs)are a key cell in TME.TAMs promote immune evasion of tumor cells in some ways by producing various cytokines and/or abnormal expression of immune checkpoint molecules.Programmed death receptor-1(PD-1)and its ligand 1(PD-L1)are important negative regulatory factors for immune cell activation.Recent studies have shown that anti-PD-1/PD-L1 therapy represents a new strategy for lymphoma immunotherapy.This article will focus on the role and expression of TAMs and PD-1/PD-L1 in lymphoma,and explore the efficacy of anti-PD-1/PD-L1 immunotherapy in different types of lymphoma.
